European journal of heart failure · 2026
Determinants and associations of health-related quality of life with mortality in acute and chronic heart failure: findings from the ESC HF III Registry.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Walli-Attaei Marjan, Lund Lars H, Luengo-Fernandez Ramon, Gray Alastair, Torbica Aleksandra, Huculeci Radu, Aboyans Victor, Timmis Adam D, Vardas Panos, Maggioni Aldo P, Leal José
Аннотация
AIMS: To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year.
METHODS: We analysed the ESC EORP Heart Failure III Registry, including patients hospitalized with acute HF or outpatient HF visits. HRQoL was assessed using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Generalized linear models examined associations between demographic, clinical, behavioural, and treatment characteristics with baseline HRQoL. Cox proportional hazards models assessed the relationship between baseline HRQoL and 1-year mortality. Changes in HRQoL were classified as improvement, deterioration, or mixed change across EQ-5D dimensions, and determinants of change were assessed using fixed-effects models.
RESULTS: Among 10 130 patients (acute HF: 38.6%; outpatient HF: 61.4%), those with acute HF had worse baseline HRQoL than outpatients. Older age, female sex, eGFR ≤29, NYHA class III/IV, and dyspnoea at rest were strongly associated with lower HRQoL in both acute and outpatient HF. Lower baseline HRQoL was associated with a higher risk of death at 1 year, with a 0.1-unit decrease in HRQoL on a scale of -0.59 to 1.00 (equivalent to 37 days of full health lost annually) associated with a 9% higher risk of death; a finding consistent across ejection fraction categories and sex. At 1-year, 45% of patients reported improved HRQoL, and improvements were more common in those with acute HF, mildly reduced ejection fraction, and women. Use of ACEi/ARBs/ARNIs was associated with a modest improvement in HRQoL at 1 year.
CONCLUSIONS: HRQoL provides important clinical information and may provide additional insight into patients' health status and disease progression beyond conventional clinical measures.
METHODS: We analysed the ESC EORP Heart Failure III Registry, including patients hospitalized with acute HF or outpatient HF visits. HRQoL was assessed using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Generalized linear models examined associations between demographic, clinical, behavioural, and treatment characteristics with baseline HRQoL. Cox proportional hazards models assessed the relationship between baseline HRQoL and 1-year mortality. Changes in HRQoL were classified as improvement, deterioration, or mixed change across EQ-5D dimensions, and determinants of change were assessed using fixed-effects models.
RESULTS: Among 10 130 patients (acute HF: 38.6%; outpatient HF: 61.4%), those with acute HF had worse baseline HRQoL than outpatients. Older age, female sex, eGFR ≤29, NYHA class III/IV, and dyspnoea at rest were strongly associated with lower HRQoL in both acute and outpatient HF. Lower baseline HRQoL was associated with a higher risk of death at 1 year, with a 0.1-unit decrease in HRQoL on a scale of -0.59 to 1.00 (equivalent to 37 days of full health lost annually) associated with a 9% higher risk of death; a finding consistent across ejection fraction categories and sex. At 1-year, 45% of patients reported improved HRQoL, and improvements were more common in those with acute HF, mildly reduced ejection fraction, and women. Use of ACEi/ARBs/ARNIs was associated with a modest improvement in HRQoL at 1 year.
CONCLUSIONS: HRQoL provides important clinical information and may provide additional insight into patients' health status and disease progression beyond conventional clinical measures.